While monocyte frequencies, in general, remained unaltered in the PB of ALS patients compared with controls (P = 0.793), ALS patients showed decreased proportions of the CD14+CD16− monocyte-subset in the PB (ALS: 84.46%, IQR 80.25–87.36; controls: 89.67%, IQR 85.79–91.37, P = 0.001), whereas CD14+CD16+ monocytes were increased (ALS: 11.71%, IQR 9.05–13.66; controls: 6.26%, IQR 5.4–10.06, P = 0.002) and CD14lowCD16+ monocyte remained unaltered (P = 0.311; Fig. 1A, left). Here, CD14 is linked to amyotrophic lateral sclerosis.